What do systematic reviews say?

Chronic lung disease in survivors · neonates with sepsis

Presence and quality of binocularity at 6 months · children with infantile esotropia

Any adverse outcome · term newborns (≥ 37 completed weeks' postmenstrual age) and preterm infants (< 37 completed weeks' postmenstrual age) up to maximum of 44…

Any adverse outcome · term newborns (≥ 37 completed weeks' postmenstrual age) and preterm infants (< 37 completed weeks' postmenstrual age) up to maximum of 44…

All‐cause mortality · Adults or children with overweight or obesity

All‐cause mortality · Adults or children with overweight or obesity

Health‐related quality of life · Adults or children with overweight or obesity

Long‐term visual acuity 20/40 or better > 2 months after treatment · people with traumatic hyphema

Final visual acuity 20/40 or better at resolution of hyphema · people with traumatic hyphema

Adverse effects: systemic hypotension · people with traumatic hyphema

Medium‐term visual acuity 20/40 or better > 2 weeks and ≤ 2 months after treatment · people with traumatic hyphema

Long‐term visual acuity 20/40 or better > 2 months after treatment · people with traumatic hyphema

Final visual acuity 20/40 or better at resolution of hyphema · people with traumatic hyphema

Medium‐term visual acuity 20/40 or better > 2 weeks and ≤ 2 months after treatment · people with traumatic hyphema

Nausea · people with traumatic hyphema

Medium‐term visual acuity 20/40 or better > 2 weeks and ≤ 2 months after treatment · people with traumatic hyphema

Neurodevelopmental disability · extremely preterm or extremely low birth weight infants

Quality of life ‐ not reported · adults with acute spontaneous intracerebral haemorrhage associated with antiplatelet drug use

Mood ‐ not reported · adults with acute spontaneous intracerebral haemorrhage associated with antiplatelet drug use

Cognitive function ‐ not reported · adults with acute spontaneous intracerebral haemorrhage associated with antiplatelet drug use